Farmers Trust Co. Sells 11,071 Shares of Gilead Sciences, Inc. $GILD

Farmers Trust Co. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 37,171 shares of the biopharmaceutical company’s stock after selling 11,071 shares during the quarter. Farmers Trust Co.’s holdings in Gilead Sciences were worth $4,126,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the sale, the chief executive officer owned 571,203 shares in the company, valued at $72,280,027.62. The trade was a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 130,257 shares of company stock worth $15,991,492 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Citigroup increased their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. UBS Group raised shares of Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Wolfe Research boosted their target price on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.13.

Gilead Sciences Stock Down 2.3%

Gilead Sciences stock opened at $120.40 on Monday. The firm has a 50 day moving average price of $121.89 and a 200-day moving average price of $115.81. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a market capitalization of $149.38 billion, a P/E ratio of 18.67, a P/E/G ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the firm posted $2.02 EPS. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.